1. Decreto Ministero Sanità 3 Marzo 2005. Caratteristiche e modalità per la donazione del sangue e di emocomponenti. Gazzetta Ufficiale n. 85 13/04/2005.
2. Legge 21 ottobre 2005, n.219. Nuova disciplina delle attivita' trasfusionali e della produzione nazionale degli emoderivati. Gazzetta Ufficiale n. 251 27/10/2005.
3. Guide to preparation, use and quality assurance of blood components, reccomandation
No R (95) 15, 18th edition, 2015.
4. Decreto Ministero Sanità 2 novembre 2015. Disposizioni relative ai requisiti di qualità e sicurezza del sangue e degli emocomponenti. Gazzetta Ufficiale n. 300 28/12/2015.
5. Bordin JO, Heddle NM, Blajchman MA. Biologic effects of leukocytes present in transfused cellular blood products. Blood. 1994 Sep 15;84(6):1703-21.
6. Bassuni WY, Blajchman MA, Al-Moshary MA. Why implement universal leukoreduction? Hematol Oncol Stem Cell Ther. 2008 Apr-Jun;1(2):106-23.
7. van de Watering LM, Hermans J, Houbiers JG, van den Broek PJ, Bouter H, Boer F, Harvey MS, Huysmans HA, Brand A. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: a randomized clinical trial. Circulation. 1998 Feb 17;97(6):562-8.
8. Bilgin YM1, van de Watering LM, Eijsman L, Versteegh MI, Brand R, van Oers MH, Brand A. Double-blind, randomized controlled trial on the effect of leukocyte-depleted erythrocyte transfusions in cardiac valve surgery. Circulation. 2004 Jun 8;109(22):2755-60. Epub 2004 May 17.
9. Sharma RR, Marwaha N. Leukoreduced blood components: Advantages and strategies for its implementation in developing countries. Asian J Transfus Sci. 2010 Jan;4(1):3-8.
10. Dzik WH. Is the febrile response to transfusion due to donor or recipient cytokine? Transfusion. 1992 Jul-Aug;32(6):594.
11. Triulzi DJ et al. Principles of Transfusion Medicine USA: Wiley-Blackwell, 2009. Leukocyte- reduced blood complement. Laboratory and clinical aspects, pp 228-46.
12. Heddle NM, Klama L, Singer J, Richards C, Fedak P, Walker I, Kelton JG. The role of the plasma from platelet concentrates in transfusion reactions. N Engl J Med. 1994 Sep 8;331(10):625-8.
13.Goodnough LT, Riddell J 4th, Lazarus H, Chafel TL, Prince G, Hendrix D, Yomtovian R.
Prevalence of platelet transfusion reactions before and after implementation of leukocyte- depleted platelet concentrates by filtration. Vox Sang. 1993;65(2):103-7.
53
14. Aye MT, Palmer DS, Giulivi A, Hashemi S. Effect of filtration of platelet concentrates on the accumulation of cytokines and platelet release factors during storage. Transfusion. 1995 Feb;35(2):117-24.
15. King KE, Shirey RS, Thoman SK, Bensen-Kennedy D, Tanz WS, Ness PM. Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs. Transfusion. 2004 Jan;44(1):25-9.
16. Rajesh K, Harsh S1, Amarjit K. Effects of Prestorage Leukoreduction on the Rate of Febrile Nonhemolytic Transfusion Reactions to Red Blood Cells in a Tertiary Care Hospital. Ann Med Health Sci Res. 2015 May-Jun;5(3):185-8. doi: 10.4103/2141-9248.157498.
17. Paglino JC, Pomper GJ, Fisch GS, Champion MH, Snyder EL. Reduction of febrile but not allergic reactions to RBCs and platelets after conversion to universal prestorage leukoreduction. Transfusion. 2004 Jan;44(1):16-24.
18.Yazer MH1, Podlosky L, Clarke G, Nahirniak SM. The effect of prestorage WBC reduction
on the rates of febrile nonhemolytic transfusion reactions to platelet concentrates and RBC. Transfusion. 2004 Jan;44(1):10-5.
19. Blajchman MA, Goldman M, Freedman JJ, Sher GD. Proceedings of a consensus conference: prevention of post-transfusion CMV in the era of universal leukoreduction. Transfus Med Rev. 2001 Jan;15(1):1-20.
20. Tegtmeier GE. Posttransfusion cytomegalovirus infections. Arch Pathol Lab Med. 1989 Mar;113(3):236-45. Review
21. Preiksaitis JK. Transfus Med Rev. 1991 Jan;5(1):1-17. Indications for the use of cytomegalovirus-seronegative blood products.
22. Preiksaitis JK. The cytomegalovirus-"safe" blood product: is leukoreduction equivalent to antibody screening? Transfus Med Rev. 2000 Apr;14(2):112-36.
23. Bowden RA, Slichter SJ, Sayers M, Weisdorf D, Cays M, Schoch G, Banaji M, Haake R, Welk K, Fisher L, McCullough J, Miller W. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion- associated CMV infection after marrow transplant. Blood. 1995 Nov 1;86(9):3598-603. 24. Cannon MJ, Operskalski EA, Mosley JW, Radford K, Dollard SC. Lack of evidence for human herpesvirus-8 transmission via blood transfusion in a historical US cohort. J Infect Dis. 2009 Jun 1;199(11):1592-8. doi: 10.1086/598859.
25. Blajchman MA1, Vamvakas EC. The continuing risk of transfusion-transmitted infections. N Engl J Med. 2006 Sep 28;355(13):1303-5.
26. Césaire R, Kérob-Bauchet B, Bourdonné O, Maier H, Amar KO, Halbout P, Dehée A, Désiré N, Dantin F, Béra O, Lézin A. Evaluation of HTLV-I removal by filtration of blood cell components in a routine setting. Transfusion. 2004 Jan;44(1):42-8.
54
27. Pietersz RN, et al. Bacterial contamination in platelet concentrates. Vox Sang. 2014
Apr;106(3):256-83. doi: 10.1111/vox.12098. Review.
28. Dzik W. Use of leukodepletion filters for the removal of bacteria. Immunol Invest. 1995 Jan-Feb;24(1-2):95-115.
29. Siblini L, Lafeuillade B, Ros A, Garraud O, Pozzetto B. Influence of blood prestorage conditions and white blood cell filtration on the bacterial load of blood deliberately inoculated with Gram-positive and Gram-negative pathogens. Vox Sang. 2004 Nov;87(4):241-9.
30. Cervia JS, Wenz B, Ortolano GA. Leukocyte reduction's role in the attenuation of infection risks among transfusion recipients. Clin Infect Dis. 2007 Oct 15;45(8):1008-13. Epub 2007 Sep 6. Review.
31. Blajchman MA, Goldman M, Baeza F. Improving the bacteriological safety of platelet transfusions. Transfus Med Rev. 2004 Jan;18(1):11-24.
32. Vasconcelos E, Seghatchian J. Bacterial contamination in blood components and preventative strategies: an overview. Transfus Apher Sci. 2004 Oct;31(2):155-63.
33. Aguzzi A. Prion diseases, blood and the immune system: concerns and reality. Haematologica. 2000 Jan;85(1):3-10.
34. Llewelyn CA, Hewitt PE, Knight RS, Amar K, Cousens S, Mackenzie J, Will RG. Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion. Lancet. 2004 Feb 7;363(9407):417-21.
35. Gregori L, McCombie N, Palmer D, Birch P, Sowemimo-Coker SO, Giulivi A, Rohwer RG Effectiveness of leucoreduction for removal of infectivity of transmissible spongiform encephalopathies from blood. Lancet. 2004 Aug 7-13;364(9433):529-31.
36. Cervia JS, Sowemimo-Coker SO, Ortolano GA, Wilkins K, Schaffer J, Wortham ST. An overview of prion biology and the role of blood filtration in reducing the risk of transfusion- transmitted variant Creutzfeldt-Jakob disease. Transfus Med Rev. 2006 Jul;20(3):190-206. 37. Wilson K, Wilson M, Hébert PC, Graham I. The application of the precautionary principle to the blood system: the Canadian blood system's vCJD donor deferral policy. Transfus Med Rev. 2003 Apr;17(2):89-94.
38. Jackman RP1, Deng X, Bolgiano D, Utter GH, Schechterly C, Lebedeva M, Operskalski E, Luban NL, Alter H, Busch MP, Slichter SJ, Norris PJ. Leukoreduction and ultraviolet treatment reduce both the magnitude and the duration of the HLA antibody response. Transfusion. 2014 Mar;54(3):672-80. doi: 10.1111/trf.12317. Epub 2013 Jun 30.
39. Seftel MD, Growe GH, Petraszko T, Benny WB, Le A, Lee CY, Spinelli JJ, Sutherland HJ, Tsang P, Hogge DE. Universal prestorage leukoreduction in Canada decreases platelet alloimmunization and refractoriness. Blood. 2004 Jan 1;103(1):333-9. Epub 2003 Sep 4.
55
40. Lannan KL, Sahler J, Spinelli SL, Phipps RP, Blumberg N. Transfusion immunomodulation- -the case for leukoreduced and (perhaps) washed transfusions. Blood Cells Mol Dis. 2013 Jan;50(1):61-8. doi: 10.1016/j.bcmd.2012.08.009. Epub 2012 Sep 13.
41. Hébert PC et al. (Leukoreduction Study Investigators). Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA. 2003 Apr 16;289(15):1941-9.
42. Anne B McDonald, Walter H Dzik. Leucodeplezione. LA TRASFUSIONE DEL SANGUE vol. 46 - num. 6 novembre-dicembre 2001 (347-361).
43. Wadhwa M, Seghatchian MJ, Dilger P, Sands D, Krailadisiri P, Contreras M, Thorpe R. Cytokines in WBC-reduced apheresis PCs during storage: a comparison of two WBC- reduction methods. Transfusion. 2000 Sep;40(9):1118-26.
44. Phelan HA, Gonzalez RP, Patel HD, Caudill JB, Traylor RK, Yancey LR, Sperry JL, Friese RS, Nakonezny PA. Prestorage leukoreduction ameliorates the effects of aging on banked blood. J Trauma. 2010 Aug;69(2):330-7. doi: 10.1097/TA.0b013e3181e0b253.
45. Phelan HA1, Eastman AL, Aldy K, Carroll EA, Nakonezny PA, Jan T, Howard JL, Chen Y, Friese RS, Minei JP. Prestorage leukoreduction abrogates the detrimental effect of aging on packed red cells transfused after trauma: a prospective cohort study. Am J Surg. 2012 Feb;203(2):198-204. Epub 2011 Sep 14.
46. Takahashi TA, Abe H, Hosoda M, Nakai K, Sekiguchi S. Bradykinin generation during filtration of platelet concentrates with a white cell-reduction filter. Transfusion. 1995 Nov- Dec;35(11):967.
47. Blumberg N, Heal JM, Gettings KF, Phipps RP, Masel D, Refaai MA, Kirkley SA, Fialkow LB. An association between decreased cardiopulmonary complications (transfusion-related acute lung injury and transfusion-associated circulatory overload) and implementation of universal leukoreduction of blood transfusions. Transfusion. 2010 Dec;50(12):2738-44. 48. Adams MR, Johnson DK, Busch MP, Schembri CT, Hartz TP, Heaton WA. Automatic volumetric capillary cytometry for counting white cells in white cell-reduced platelet apheresis components. Transfusion. 1997 Jan;37(1):29-37.
49. Dzik S. Principles of counting low numbers of leukocytes in leukoreduced blood components. Transfus Med Rev. 1997 Jan;11(1):44-55.
50. Rebulla P, Dzik WH. Multicenter evaluation of methods for counting residual white cells in leukocyte-depleted red blood cells. The Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion. Vox Sang. 1994;66(1):25- 32.
51. Sadoff BJ, Dooley DC, Kapoor V, Law P, Friedman LI, Stromberg RR. Methods for measuring a 6 log10 white cell depletion in red cells. Transfusion. 1991 Feb;31(2):150-5.
56
52. Dzik WH, Ragosta A, Cusack WF. Flow-cytometric method for counting very low numbers of leukocytes in platelet products. Vox Sang. 1990;59(3):153-9.
53. Dijkstra-Tiekstra MJ, van der Meer PF, Pietersz RN, de Wildt-Eggen J. Multicenter evaluation of two flow cytometric methods for counting low levels of white blood cells. Transfusion. 2004 Sep;44(9):1319-24.
54. Barclay R, Walker B, Allan R, Reid C, Duffin E, Kane E, Turner M. Flow cytometric determination of residual leucocytes in filter-depleted blood products: an evaluation of Becton-Dickinson's LeucoCOUNT system. Transfus Sci. 1998 Dec;19(4):399-403.
55. Krailadsiri P, Seghatchian MJ. III-7 evaluation of IMAGN 2000: a new system for absolute leucocyte count. Transfus Sci. 1998 Dec;19(4):405-7.
56. Tanaka Y, Matsushita H, Tanaka Y, Maruki Y, Kondo T, Asai S, Miyachi H. Evaluation of the body fluid mode of automated hematology analyzer XN-series for extremely low peripheral white blood cell counts. Int J Lab Hematol. 2014 Feb;36(1):e3-7. Epub 2013 May 30.
57. Fleming C, Brouwer R, Lindemans J, de Jonge R. Validation of the body fluid module on the new Sysmex XN-1000 for counting blood cells in cerebrospinal fluid and other body fluids. Clin Chem Lab Med. 2012 Oct 1;50(10):1791-8.
58. C Briggs, I Longair, P Kumar & SJ Machin Sysmex XN Analysers – A Novel Modular Blood
Cell Counting System.Journal of clinical pathology 65(11):1024-30, July 2012.
59. Buoro S, Mecca T, Azzarà G, Seghezzi M, Dominoni P, Crippa A, Ottomano C, Lippi G. Cell Population Data and reflex testing rules of cell analysis in pleural and ascitic fluids using body fluid mode on Sysmex XN-9000. Clin Chim Acta. 2016 Jan 15; 452:92-8.
60. J. Linssen, V. Jennissen, J. Hildmann, E. Reisinger, J. Schindler, G. Malchau, A. Nierhaus, and K. Wielckens. Identification and Quantification of HighFluorescence-Stained Lymphocytes as Antibody Synthesizing/Secreting Cells Using the Automated Routine Hematology AnalyzerXE-2100. Cytometry Part B (Clinical Cytometry) 72B:157–166 (2007). 61 Brando B, Barnett D, Janossy G, Mandy F, Autran B, Rothe G, Scarpati B, D'Avanzo G, D'Hautcourt JL, Lenkei R, Schmitz G, Kunkl A, Chianese R, Papa S, Gratama JW. Cytofluorometric methods for assessing absolute numbers of cell subsets in blood. European Working Group on Clinical Cell Analysis. Cytometry. 2000 Dec 15;42(6):327-46
62 Fleming C, Russcher H, Lindemans J, de Jonge R. Clinical relevance and contemporary methods for counting blood cells in body fluids suspected of inflammatory disease. Clin Chem Lab Med. 2015 Oct;53(11):1689-706.
63. Matteo Vidali, Michele Tronchin, Ruggero Dittadi per il Gruppo di Studio SIBioC “Statistica per il Laboratorio”. PROTOCOLLO OPERATIVO PER LA COMPARAZIONE DI DUE METODI ANALITICI NEI LABORATORI CLINICI.
57
64. Kazuaki Yamamoto, Yuichi Domae, Shomi Koyama, Michio Hagihara, Shuji Tohda, Naoko Tojo. Evaluation of analytical performance of XN-9000. Atti congressuali da Japanase Association of Medical Technologists.
65. XN series per il Sistema XN-9000. Istruszioni per l’uso. Sysmex Corporation KOBE Giappone.